Global Fecal Transplant Therapy Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

PUBLISHED: May 6, 2024

PAGES: 189 Pages

DELIVERY TIME: 1-2 business days

ADD TO COMPARE

SELECT AN OPTION

The global demand for Fecal Transplant Therapy Market is presumed to reach the market size of nearly USD 3.24 Billion by 2032 from USD 1.89 Billion in 2023 with a CAGR of 6.18% under the study period 2024-2032.

Fecal transplant therapy, or fecal microbiota transplantation (FMT), is a medical procedure involving fecal matter from a healthy donor that is transferred into a recipient's gastrointestinal tract to reinstate a healthy balance of gut microbiota. This therapy primarily treats recurrent Clostridium difficile (C. difficile) infections, a bacterial infection that causes severe diarrhea and gastrointestinal symptoms. This therapy works by reintroducing beneficial bacteria and microorganisms from the donor's stool into the recipient's gut, which helps suppress the growth of harmful bacteria such as C. difficile and restore microbial diversity and balance. This therapy has shown high success rates in treating recurrent C. difficile infections and is being investigated for its potential applications in other gastrointestinal disorders and conditions.

MARKET DYNAMICS

The spurring prevalence of gastrointestinal disorders, such as inflammatory bowel disease (IBD), clostridium difficile infection (CDI), and irritable bowel syndrome (IBS), is driving the demand for innovative treatment options. The increasing understanding of the gut-brain axis and the role of gut microbiota in overseeing immune function, metabolism, and neurological health drives interest in fecal transplant therapy as a potential therapeutic approach for conditions such as depression, autism spectrum disorders, and Parkinson's disease. Moreover, advancements in fecal processing techniques, such as frozen, lyophilized, or encapsulated formulations, are improving the convenience, stability, and standardization of fecal transplant products, thereby facilitating broader adoption and scalability of the therapy. Furthermore, supportive regulatory frameworks and guidelines for fecal transplant therapy, coupled with increasing reimbursement coverage by healthcare payers, are removing barriers to access and driving market expansion. Additionally, the emergence of microbiome-based diagnostics and personalized medicine approaches is creating new opportunities for fecal transplant therapy as part of comprehensive treatment strategies tailored to individual patients' microbiome profiles and medical needs. However, advancements in microbiome research and alternative treatment modalities may challenge the market growth in the coming years.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Fecal Transplant Therapy. The growth and trends of Fecal Transplant Therapy industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Fecal Transplant Therapy market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Disease

Clostridium Difficile Infection
Autism, Obesity
Parkinson's Disease (PD)
Diabetes Mellitus
Others

By Procedure

Fecal Enema
Fecal Bacteriotherapy
Stool Transplant
Human Probiotic Infusion
Fecal Transfusion

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Fecal Transplant Therapy market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Fecal Transplant Therapy market include Finch Therapeutics, Rebiotix, Vedanta Biosciences, Seres Therapeutics, DuPont Nutrition & Biosciences, OpenBiome, Evelo Biosciences, Microbiome Therapeutics, Daewoong Pharmaceutical, Takeda Pharmaceutical Company, MaaT Pharma, BiomX, Assembly Biosciences, Microbiotica, CIPAC Therapeutics. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

Product Code: VMR112114443

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. FECAL TRANSPLANT THERAPY - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Disease
- 3.7.2 Market Attractiveness Analysis By Procedure
- 3.7.3 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL FECAL TRANSPLANT THERAPY MARKET ANALYSIS BY DISEASE

5.1. Overview By Disease
5.2. Historical and Forecast Data
5.3. Analysis By Disease
5.4. Clostridium Difficile Infection Historic and Forecast Sales By Regions
5.5. Autism, Obesity Historic and Forecast Sales By Regions
5.6. Parkinson's Disease (PD) Historic and Forecast Sales By Regions
5.7. Diabetes Mellitus Historic and Forecast Sales By Regions
5.8. Others Historic and Forecast Sales By Regions

6. GLOBAL FECAL TRANSPLANT THERAPY MARKET ANALYSIS BY PROCEDURE

6.1. Overview By Procedure
6.2. Historical and Forecast Data
6.3. Analysis By Procedure
6.4. Fecal Enema Historic and Forecast Sales By Regions
6.5. Fecal Bacteriotherapy Historic and Forecast Sales By Regions
6.6. Stool Transplant Historic and Forecast Sales By Regions
6.7. Human Probiotic Infusion Historic and Forecast Sales By Regions
6.8. Fecal Transfusion Historic and Forecast Sales By Regions

7. GLOBAL FECAL TRANSPLANT THERAPY MARKET ANALYSIS BY GEOGRAPHY

7.1. Regional Outlook
7.2. Introduction
7.3. North America Sales Analysis
- 7.3.1 Overview, Historic and Forecast Data Sales Analysis
- 7.3.2 North America By Segment Sales Analysis
- 7.3.3 North America By Country Sales Analysis
- 7.3.4 United States Sales Analysis
- 7.3.5 Canada Sales Analysis
- 7.3.6 Mexico Sales Analysis
7.4. Europe Sales Analysis
- 7.4.1 Overview, Historic and Forecast Data Sales Analysis
- 7.4.2 Europe By Segment Sales Analysis
- 7.4.3 Europe By Country Sales Analysis
- 7.4.4 United Kingdom Sales Analysis
- 7.4.5 France Sales Analysis
- 7.4.6 Germany Sales Analysis
- 7.4.7 Italy Sales Analysis
- 7.4.8 Russia Sales Analysis
- 7.4.9 Rest Of Europe Sales Analysis
7.5. Asia Pacific Sales Analysis
- 7.5.1 Overview, Historic and Forecast Data Sales Analysis
- 7.5.2 Asia Pacific By Segment Sales Analysis
- 7.5.3 Asia Pacific By Country Sales Analysis
- 7.5.4 China Sales Analysis
- 7.5.5 India Sales Analysis
- 7.5.6 Japan Sales Analysis
- 7.5.7 South Korea Sales Analysis
- 7.5.8 Australia Sales Analysis
- 7.5.9 South East Asia Sales Analysis
- 7.5.10 Rest Of Asia Pacific Sales Analysis
7.6. Latin America Sales Analysis
- 7.6.1 Overview, Historic and Forecast Data Sales Analysis
- 7.6.2 Latin America By Segment Sales Analysis
- 7.6.3 Latin America By Country Sales Analysis
- 7.6.4 Brazil Sales Analysis
- 7.6.5 Argentina Sales Analysis
- 7.6.6 Peru Sales Analysis
- 7.6.7 Chile Sales Analysis
- 7.6.8 Rest of Latin America Sales Analysis
7.7. Middle East & Africa Sales Analysis
- 7.7.1 Overview, Historic and Forecast Data Sales Analysis
- 7.7.2 Middle East & Africa By Segment Sales Analysis
- 7.7.3 Middle East & Africa By Country Sales Analysis
- 7.7.4 Saudi Arabia Sales Analysis
- 7.7.5 UAE Sales Analysis
- 7.7.6 Israel Sales Analysis
- 7.7.7 South Africa Sales Analysis
- 7.7.8 Rest Of Middle East And Africa Sales Analysis

8. COMPETITIVE LANDSCAPE OF THE FECAL TRANSPLANT THERAPY COMPANIES

8.1. Fecal Transplant Therapy Market Competition
8.2. Partnership/Collaboration/Agreement
8.3. Merger And Acquisitions
8.4. New Product Launch
8.5. Other Developments

9. COMPANY PROFILES OF FECAL TRANSPLANT THERAPY INDUSTRY

9.1. Top Companies Market Share Analysis
9.2. Market Concentration Rate
9.3. Finch Therapeutics
- 9.3.1 Company Overview
- 9.3.2 Company Revenue
- 9.3.3 Products
- 9.3.4 Recent Developments
9.4. Rebiotix
- 9.4.1 Company Overview
- 9.4.2 Company Revenue
- 9.4.3 Products
- 9.4.4 Recent Developments
9.5. Vedanta Biosciences
- 9.5.1 Company Overview
- 9.5.2 Company Revenue
- 9.5.3 Products
- 9.5.4 Recent Developments
9.6. Seres Therapeutics
- 9.6.1 Company Overview
- 9.6.2 Company Revenue
- 9.6.3 Products
- 9.6.4 Recent Developments
9.7. DuPont Nutrition & Biosciences
- 9.7.1 Company Overview
- 9.7.2 Company Revenue
- 9.7.3 Products
- 9.7.4 Recent Developments
9.8. OpenBiome
- 9.8.1 Company Overview
- 9.8.2 Company Revenue
- 9.8.3 Products
- 9.8.4 Recent Developments
9.9. Evelo Biosciences
- 9.9.1 Company Overview
- 9.9.2 Company Revenue
- 9.9.3 Products
- 9.9.4 Recent Developments
9.10. Microbiome Therapeutics
- 9.10.1 Company Overview
- 9.10.2 Company Revenue
- 9.10.3 Products
- 9.10.4 Recent Developments
9.11. Daewoong Pharmaceutical
- 9.11.1 Company Overview
- 9.11.2 Company Revenue
- 9.11.3 Products
- 9.11.4 Recent Developments
9.12. Takeda Pharmaceutical Company
- 9.12.1 Company Overview
- 9.12.2 Company Revenue
- 9.12.3 Products
- 9.12.4 Recent Developments
9.13. MaaT Pharma
- 9.13.1 Company Overview
- 9.13.2 Company Revenue
- 9.13.3 Products
- 9.13.4 Recent Developments
9.14. BiomX
- 9.14.1 Company Overview
- 9.14.2 Company Revenue
- 9.14.3 Products
- 9.14.4 Recent Developments
9.15. Assembly Biosciences
- 9.15.1 Company Overview
- 9.15.2 Company Revenue
- 9.15.3 Products
- 9.15.4 Recent Developments
9.16. Microbiotica
- 9.16.1 Company Overview
- 9.16.2 Company Revenue
- 9.16.3 Products
- 9.16.4 Recent Developments
9.17. CIPAC Therapeutics
- 9.17.1 Company Overview
- 9.17.2 Company Revenue
- 9.17.3 Products
- 9.17.4 Recent Developments